Effect of pirfenidone on renal tubulointerstitial
fibrosis

doi:10.1007/s11684-009-0045-2

Front. Med.

2009, Vol. 3

Issue (3) : 316-322 https://doi.org/10.1007/s11684-009-0045-2

Research articles

Effect of pirfenidone on renal tubulointerstitial fibrosis

Dixin LI MM , Hongbing ZENG MD , Chunyang JI MM ,

Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;

Download: PDF(452 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Renal tubulointerstitial fibrosis (TIF) is the common end stage of various chronic renal diseases, and pirfenidone (PFD) is a novel, broad-spectrum anti-fibrotic compound but little is known about its effect and mechanism of action on renal TIF. In this work, we employed a unilateral ureteral obstruction (UUO) rat model to investigate the apoptosis of renal tubular epithelial cells (RTC) after PFD treatment. Thirty-five Sprague Dawley (SD) rats were randomized into three groups: sham-operated group (n=7), UUO group (n=14) and PFD group (n=14). All rats were sacrificed at day 7 or 14 after operation. Renal histology was studied by using periodic acid schiff reagent (PAS) and Masson trichromic stain (MASSON); apoptosis was detected by in situ terminal deoxynucleotide transferase-mediated dUTP-biotin nick end-labeling (TUNEL); tubular caspase-3 expression was assessed by immunohistochemistry. The content of malondialdehyde (MDA) and total activity of superoxide dismutase (T-SOD) in the renal cortex was determined by chemical colorimetry method. TIF, apoptosis of RTC, tubular expression of caspase-3 and the content of MDA were increased in the UUO group compared with those in the sham-operated group, and were ameliorated significantly by PFD treatment (P<0.05). The activity of SOD was decreased in the UUO group, but was improved by PFD treatment (P<0.05). Our results showed that PFD could ameliorate TIF in the UUO group, and the possible mechanism was by reducing the apoptosis of RTC, which involved oxidative stress and caspase-3.

Keywords pirfenidone apoptosis caspase 3 oxidative stress

Issue Date: 05 September 2009

Cite this article:

Dixin LI MM,Chunyang JI MM,Hongbing ZENG MD. Effect of pirfenidone on renal tubulointerstitial fibrosis[J]. Front. Med., 2009, 3(3): 316-322.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0045-2
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I3/316

	Nagata S. Apoptosis by death factor. Cell, 1997, 88(3): 355―365 doi: 10.1016/S0092-8674(00)81874-7
	Truong L D, Choi Y J, Tsao C C, Ayala G, Sheikh-Hamad D, Nassar G, Suki W N. Renal cellapoptosis in chronic obstructive uropathy: the roles of caspases. Kidney Int, 2001, 60(3): 924―934 doi: 10.1046/j.1523-1755.2001.060003924.x
	Gobe G C, Axelsen R A. Genesis of renal tubularatrophy in experimental hydronephrosis in the rat. Role of apoptosis. Lab Invest, 1987, 56(3): 273―281
	Hagimoto N, Kuwano K, Kawasaki M, Yoshimi M, Kaneko Y, Kunitake R, Maeyama T, Tanaka T, Hara N. Induction of interleukin-8 secretion and apoptosis inbronchiolar epithelial cells by Fas ligation. Am J Respir Cell Mol Boil, 1999, 21(3): 436―445
	Faouzi S, Burckhardt B E, Hanson J C, Campe C B, Schrum L W, Rippe R A, Maher J J. Anti-fas induces hepaticchemokines and promotes inflammation by an NFκB-independent,caspase-3-dependent pathway. J Biol Chem, 2001, 276(52): 49077―49082 doi: 10.1074/jbc.M109791200
	Docherty N G, O'Sullivan O E, Healy D A, Fitzpatrick J M, Watson R W. Evidence that inhibitionof tubular cell apoptosis protects against renal damage and developmentof fibrosis following ureteric obstruction. Am J Physiol Renal Physiol, 2006, 290(1): 4―13 doi: 10.1152/ajprenal.00045.2005
	Daemen M A, van’t Veer C, Denecker G, Heemskerk V H, WolfsClauss M TG, Vandenabeele P, Buurman W A. Inhibition of apoptosis induced by ischemia-reperfusionprevents inflammation. J Clin Invest, 1999, 104(5): 541―549 doi: 10.1172/JCI6974
	Choi Y J, Baranowska-Daca E, Nguyen V, Koji T, Ballantyne C M, Sheikh-Hamad D, Suki W N, Truong L D. Mechanism of chronic obstructive uropathy:increased expression of apoptosis-promoting molecules. Kidney Int, 2000, 58(4): 1481―1491 doi: 10.1046/j.1523-1755.2000.00310.x
	Raghu G, Johnson W C, Lockhart D, Mageto Y. Treatmentof idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open label Phase II study. Am J Respir Crit Care Med, 1999, 159(4 pt1): 1061―1069
	Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment withpirfenidone to patients with chronic pulmonary fibrosis. Intern Med, 2002, 41(12): 1118―1123 doi: 10.2169/internalmedicine.41.1118
	Iyer S N, Gurujeyalakshmi G, Giri S N. Effects of pirfenidone on procollagen gene expressionat the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther, 1999, 289(1): 211―218
	Armendáriz-Borunda J, Islas-Carbajal MC, Meza-García E, Rincón A R, Lucano S, Sandoval A S, Salazar A, Berumen J, Alvarez A, Covarrubias A, Aréchiga G, García L. A pilot study in patientswith established advanced liver fibrosis using pirfenidone. Gut, 2006, 55(11): 1663―1665 doi: 10.1136/gut.2006.107136
	García L, Hernández I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin S, Armendariz-Borunda J. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol, 2002, 37(6): 797―805 doi: 10.1016/S0168-8278(02)00272-6
	Mirkovic S, Seymour A M, Fenning A, Strachan A, Margolin S B, Taylor S M, Brown L. Attenuationof cardiac fibrosis by pirfenidone and amiloride in DOCA2 salt hypertensiverats. Br J Pharmacol, 2002, 135(4): 961―968 doi: 10.1038/sj.bjp.0704539
	Miric G, Dallemagne C, Endre Z, Margolin S, Taylor S M, Brown L. Reversal of cardiac and renal fibrosis by pirfenidoneand spironolactone in streptozotocin diabetic rats. Br J Pharmacol, 2001, 133(5): 687―694 doi: 10.1038/sj.bjp.0704131
	Cho M E, Smith D C, Branton M H, Penzak S R, Kopp J B. Pirfenidone slows renal function declinein patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol, 2007, 2(5): 906―913 doi: 10.2215/CJN.01050207
	Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin S B, Kurokawa K. Pirfenidone improves renal function and fibrosis in thepostobstructed kidney. Kidney Int, 1998, 54(1): 99―109 doi: 10.1046/j.1523-1755.1998.00962.x
	Hewitson T D, Kelynack K J, Tait M G, Martic M, Jones C L, Margolin S B, Becker G J. Pirfenidone reduces in vitrorat renal fibroblast activation and mitogenesis. J Nephrol, 2001, 14(6): 453―460
	Shihab F S, Bennett W M, Yi H, Andoh T F. Effect ofPirfenidone on Apoptosis-Regulatory Genes in Chronic CyclosporineNephrotoxicity. Transplantation, 2005, 79(4): 419―426 doi: 10.1097/01.TP.0000151721.99418.48
	Lieberthal W, Triaca V, Levine J. Mechanism s of death induced by cisplatin in proximaltubular epithelial cells: apoptosis vs necrosis. Am J Physiol, 1996, 270(4 Pt 2): F700―708
	Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, Brodsky S, Goligorsky M S. Oxidative and nitrosativestress in acute renal ischemia. Am J PhysiolRenal Physiol, 2001, 281(5): F948―957
	Ricardo S D, Ding G, Eufemio M, Diamond J R. Antioxidant expression in experimental hydronephrosis: role of mechanicalstretch and growth factors. Am J PhysiolRenal Physiol, 1997, 272(6 Pt 2): 789―798
	Sugiyama H, Kobayashi M, Wang D H, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H. Telmisartaninhibits both oxidative stress and renal fibrosis after unilateralureteral obstruction in acatalasemic mice. Nephrol Dial Transplant, 2005, 20(12): 2670―2680 doi: 10.1093/ndt/gfi045
	Klahr S, Morrissey J. Obstructive nephropathy andrenal fibrosis. Am J Physiol Renal Physiol, 2002, 283(5): F861―F875
	Li M, Ona V O, Guégan C, Chen M, Jackson-Lewis V, Andrews L J, Olszewski A J, Stieg P E, Lee J P, Przedborski S, Friedlander R M. Functional role of caspase-1and caspase-3 in an ALS transgenic mouse model. Science, 2000, 288(5464): 335―339 doi: 10.1126/science.288.5464.335
	Cuttle L, Zhang X J, Endre Z H, Winterford C, Gobe G C. Bcl-X(L) translocation inrenal tubular epithelial cells in vitro protects distal cells fromoxidative stress. Kidney Int, 2001, 59(5): 1779―1788 doi: 10.1046/j.1523-1755.2001.0590051779.x
	Nowzari F B, Davidson S D, Eshghi M, Mallouh C, Tazaki H, Konno S. Adverse effects of oxidative stress on renal cells andits prevention by antioxidants. Mol Urol, 2000, 4(1): 15―19
	Emanuele S, Calvaruso G, Lauricella M, Giuliano M, Bellavia G, D'Anneo A, Vento R, Tesoriere G. Apoptosis induced in hepatoblastomaHepG2 cells by the proteasome inhibitor MG132 is associated with hydrogenperoxide production, expression of Bcl-XS and activation of caspase-3. Int J Oncok, 2002, 21(4): 857―865
	Tian B, Liu J, Bitterman P B, Bache R J. Mechanismsof cytokine induced NO-mediated cardiac fibroblast apoptosis. Am J Physiol Heart Circ Physiol, 2002, 283(5): H1958―1967
	Woo S H, Park I C, Park M J, Lee H C, Lee S J, Chun Y J, Lee S H, Hong S I, Rhee C H. Arsenictrioxide induces apoptosis through a reactive oxygen species-dependentpathway and loss of mito-chondrial membrane potential in HeLa cells. Int J Oncol, 2002, 21(1): 57―63
	Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agentpirfenidone suppresses tumor necrosis factor2alpha at the translationallevel. Eur J Pharmacol, 2002, 446(123): 177―185 doi: 10.1016/S0014-2999(02)01758-2

[1]	Pengju Zhang, Tao Li, Xingyun Wu, Edouard C. Nice, Canhua Huang, Yuanyuan Zhang. Oxidative stress and diabetes: antioxidative strategies[J]. Front. Med., 2020, 14(5): 583-600.
[2]	Qiuxia Han, Hanyu Zhu, Xiangmei Chen, Zhangsuo Liu. Non-genetic mechanisms of diabetic nephropathy[J]. Front. Med., 2017, 11(3): 319-332.
[3]	Amma Owusu-Ansah,Sung Hee Choi,Agne Petrosiute,John J. Letterio,Alex Yee-Chen Huang. Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review[J]. Front. Med., 2015, 9(1): 46-56.
[4]	Hui XIAO PhD, Ming TIAN MM, Junna GE MM, Xin Wei MD, Zhaoming LI MM, Xiaolan LI MS, Deding TAO PhD, Junbo HU MD, Jianping GONG MD, . The role of CDK1 siRNA interference in cell cycle and cell apoptosis[J]. Front. Med., 2009, 3(4): 384-389.
[5]	Yuan ZHANG MD , Xiaoyan ZHANG MM , Yanhui LI MM , Xuan DU MM , Zehua WANG MD, PhD , Hongbo WANG MD , . Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells [J]. Front. Med., 2009, 3(3): 341-346.
[6]	Qiong CHEN, Qing YU, Yuhu SONG, Peiyuan Li, Ying CHANG, Zhijun WANG, Lifeng LIU, Wei WU, Jusheng LIN. Cloning of human XAF1 gene promoter and assay of its transcription activity in a variety of cell lines[J]. Front Med Chin, 2009, 3(2): 148-152.
[7]	Jianwen REN, Zhenhui PENG, Birong GUO, Min PAN. Celecoxib in combination with retinoid CD437 inhibits melanoma A375 cell in vitro[J]. Front Med Chin, 2009, 3(1): 108-112.
[8]	Qi RUI, Qin LU, Dayong WANG. Administration with Bushenkangshuai Tang alleviates UV irradiation- and oxidative stress-induced lifespan defects in nematode Caenorhabditis elegans[J]. Front Med Chin, 2009, 3(1): 76-90.
[9]	ZHANG Shilong, ZENG Fuqing, PENG Shibo, WANG Liang. Effect on proliferation and apoptosis of T24 cell lines via silencing DNMT1 with RNA interference[J]. Front. Med., 2008, 2(4): 374-379.
[10]	ZHAN Rong, YU Qinghong, HUANG Haobo. Effect of arsenic trioxide on proliferation and apoptosis of U266 cells and its relationship with the expression variation of VEGF[J]. Front. Med., 2008, 2(4): 356-360.
[11]	LU Yi, QU Bo, LIU Chang, YU Liang, Liu Xuemin, WANG Haohua, JIANG An, ZHANG Xiaogang. Mechanism of hepatocellular damage in rat caused by low serum selenium[J]. Front. Med., 2008, 2(3): 255-258.
[12]	SU Yuan, JIN Yang, ZHANG Xiaoju, ZHOU Qiong, BAI Ming, ZHU Liping. Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549[J]. Front. Med., 2007, 1(4): 359-363.
[13]	OUYANG Shan, ZHANG Qinghua, QIAO Fuyuan. Relationship between expression of hepatocyte grow factor and apoptosis of trophoblasts in hypertensive disorder complicating pregnancy[J]. Front. Med., 2007, 1(4): 386-389.
[14]	CAO Jie, LI Wanglin, XIA Jie, TANG Weibiao, WANG Hui, CHEN Xiwen, XIAO Huanqing, LI Yuyuan, CHEN Xiaoping, DU Hong, CHEN Shanming. Absence of FHIT expression is associated with apoptosis inhibition in colorectal cancer[J]. Front. Med., 2007, 1(2): 147-156.
[15]	HE Zhongye, GUO Renxuan, LI Yang, XIE Chengyao, LIU Nan, SONG Wen. Alleviation of cell damage in experimental ANP in rats by administration of chondroitin-sulfate reduces[J]. Front. Med., 2007, 1(1): 36-40.

Viewed

Full text

Abstract

Cited

Shared

Discussed